(Alliance News) - PureTech Health PLC on Wednesday said that it has started the next stage of trials for LYT-300, in order to test whether the therapy could be used to treat anxiety disorders. Read More
(Alliance News) - PureTech Health PLC on Wednesday said its founded entity, Akili Inc, released an attention deficit hyperactivity disorder treatment for adult patients. Read More
(Alliance News) - PureTech Health PLC on Tuesday said its founded entity, Vedanta Biosciences, has been granted fast track designation from the US Food & Drug Administration for its bacterial consortium candidate, VE303, for the prevention of recurrent Clostridioides difficile infection. Read More
PureTech Health PLC - Boston-based biotechnology company - Says its founded entity, Akili, announced clinical trial for video game-based therapy, EndeavorRx, showed improvement in attention and quality of life for people with attention deficit hyperactivity disorder. Notes attention improved in more than 80% of adults with ADHD, while over a third of participants "no longer exhibited an attention deficit following treatment." Read More
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning: Read More
(Alliance News) - PureTech Health PLC on Friday said its loss widened in 2022 and revenue declined, though it hailed an "exceptional" year and expects further success in 2023. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on xxxday and not separately reported by Alliance News: Read More
(Alliance News) - PureTech Health PLC on Monday said that its founded entity, Vedanta Biosciences, has seen positive results for its lead programme, VE303. Read More
(Alliance News) - Stock prices in London were largely lower at midday on Thursday, raised UK interest rates by 25 basis points on Thursday, as widely expected, and indicated that further tightening in monetary policy may be required. Read More
(Alliance News) - PureTech Health PLC on Thursday said Royalty Pharma PLC has acquired an interest in PureTech's royalty in Karuna Therapeutics Inc's KarXT schizophrenia treatment. Read More
(Alliance News) - PureTech Health PLC on Monday said its founded entity, Karuna Therapeutics Inc announced its phase 3 EMERGENT-3 trial of KarXT in Schizophrenia has met its primary endpoint. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More
PureTech Health PLC - clinical-stage biotherapeutics company - Says it will advance LYT-300 for the potential treatment of anxiety disorders and post-partum depression. A placebo-controlled, phase 2a, proof-of-concept, social anxiety clinical trial is expected to begin in the first half of 2023. Results are expected by the end of the year. An open-label, phase 2a, proof-of-concept clinical trial in women with post-partum depression is expected to begin in the second half of 2023. Read More
(Alliance News) - PureTech Health PLC on Friday said the topline results for the pivotal trial of its EndeavorRx treatment showed "robust improvements in attention and broader clinical outcomes". Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More
(Alliance News) - PureTech Health PLC on Friday said that its founded entity, Sonde Health Inc, has completed a Series B investment round for the development of its voice-based health monitoring technology. Read More
(Alliance News) - PureTech Health PLC on Thursday announced that its founded entity Vor Biopharma Inc has successfully transplanted its investigational trem-Cel into a patient with acute myeloid leukemia. Read More
(Alliance News) - PureTech Health PLC on Wednesday said that it had advanced LYT-310, an oral form of cannabidiol (CBD) prodrug toward clinical studies. Read More
(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday: Read More